The trial enrolled patients with advanced HER2-mutated NSCLC that was refractory to treatment, with the primary endpoint being clinical benefit (CB), defined as either achieving an objective response or maintaining stable disease for a minimum of 16 weeks. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.